Geneos Wealth Management’s Nektar Therapeutics NKTR Stock Holding History

Geneos Wealth Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-17	Closed	–	–	2069
2022 Q3	$0	Sell	17 -12	-41%	-$714	﹤0.01%	2387
2022 Q2	$1K	Hold	29	–	–	﹤0.01%	2521
2022 Q1	$2K	Hold	29	–	–	﹤0.01%	2560
2021 Q4	$5K	Sell	29 -7	-19%	-$1.52K	﹤0.01%	2408
2021 Q3	$9K	Hold	36	–	–	﹤0.01%	2261
2021 Q2	$9K	Hold	36	–	–	﹤0.01%	2235
2021 Q1	$10K	Hold	36	–	–	﹤0.01%	2387
2020 Q4	$10K	Sell	36 -24	-40%	-$6.2K	﹤0.01%	2219
2020 Q3	$15K	Hold	60	–	–	﹤0.01%	1790
2020 Q2	$19K	Hold	60	–	–	﹤0.01%	1646
2020 Q1	$15K	Hold	60	–	–	﹤0.01%	1633
2019 Q4	$19K	Hold	60	–	–	﹤0.01%	1707
2019 Q3	$16K	Sell	60 -10	-14%	-$3.67K	﹤0.01%	1711
2019 Q2	$37K	Sell	70 -7	-9%	-$3.51K	﹤0.01%	1344
2019 Q1	$38K	Hold	77	–	–	﹤0.01%	1275
2018 Q4	$38K	Sell	77 -5	-6%	-$3.02K	﹤0.01%	1226
2018 Q3	$75K	Hold	82	–	–	0.01%	989
2018 Q2	$60K	Buy	82 +39	+91%	+$45K	﹤0.01%	965
2018 Q1	$68K	Buy	+43	New	+$55.4K	0.01%	884

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Geneos Wealth Management's NKTR Position: Q4 2022 in Review

Geneos Wealth Management sold out of Nektar Therapeutics (NKTR) in Q4 2022, closing a stake of 17 shares.

Geneos Wealth Management first reported a position in NKTR in Q1 2018 and held it in 19 quarters. The position peaked at $75K in Q3 2018. 214 funds tracked by Wall St. Rank hold NKTR as of Q4 2022.

Geneos Wealth Management reported no remaining Nektar Therapeutics position as of Q4 2022 after selling out during the quarter.
Geneos Wealth Management sold 17 Nektar Therapeutics shares in Q4 2022.
Geneos Wealth Management first reported a position in Nektar Therapeutics in Q1 2018 and held it in 19 quarters.
Geneos Wealth Management's Nektar Therapeutics position peaked at $75K in Q3 2018.
214 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2022.

Based on Geneos Wealth Management's 13F filing for Q4 2022, filed 31 Jan 2023.